The Angiotensin Receptor: Potential Drug Targets and Biomarkers

Target Name: Angiotensin receptor (AT)

NCBI ID: P5789

Angiotensin receptor (AT)

Other Name(s): AT

The Angiotensin Receptor: Potential Drug Targets and Biomarkers

The Angiotensin receptor (AT) is a protein that is expressed in various tissues throughout the body, including the heart, kidneys, lungs, and intestines. It is a member of the superfamily of G protein-coupled receptors, which are a family of transmembrane proteins that play an important role in cellular signaling.

The AT is involved in a wide range of physiological processes in the body, including blood pressure, blood volume, and inflammation. It is thought to be involved in the regulation of blood pressure by decreasing the volume of blood and increasing the resistance to blood pressure. It is also involved in the regulation of blood volume by increasing the contractility of blood vessels. Additionally, the AT is thought to be involved in the regulation of inflammation by promoting the production of pro-inflammatory cytokines.

Despite the importance of the AT in various physiological processes, several surveys have suggested that it may also be a potential drug target or biomarker. The AT is known to be involved in a variety of signaling pathways, including the regulation of pain, inflammation, and blood pressure. It is also known to be involved in the regulation of cellular processes such as cell growth, apoptosis, and angiogenesis.

One potential drug target for the AT is the inhibition of angiotensin receptor antagonists (ARAs), which are drugs that are used to treat hypertension and heart failure. ARAs work by blocking the action of angiotensin, a hormone that is produced by the adrenal gland in response to stress and other stimuli. The production of angiotensin has been shown to be increased in individuals with hypertension and heart failure, and the use of ARAs has been shown to improve these conditions in some individuals.

Another potential drug target for the AT is the inhibition of angiotensin receptor kinases (ARKs), which are enzymes that are involved in the signaling pathway of the AT. ARKs are thought to play a role in the regulation of various cellular processes, including cell growth, apoptosis, and angiogenesis. The use of ARK inhibitors has been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and inflammatory diseases.

In addition to its potential as a drug target, the AT is also potential as a biomarker for several diseases. The AT has been shown to be involved in the regulation of various physiological processes, including blood pressure, blood volume, and inflammation. It is therefore potential to be used as a biomarker for conditions such as hypertension, heart failure, and neurodegenerative diseases. The use of the AT as a biomarker may have the advantage of being non-invasive and being able to provide information about the underlying biological processes that are causing a disease.

In conclusion, the Angiotensin receptor (AT) is a protein that is involved in a wide range of physiological processes in the body. It is a member of the superfamily of G protein-coupled receptors and is thought to be involved in the regulation of blood pressure, blood volume, and inflammation. The AT is also potential as a drug target or biomarker for several diseases, including hypertension, heart failure, and neurodegenerative diseases. Further research is needed to fully understand the role of the AT in these and other processes.

Protein Name: Angiotensin Receptor (AT) (nonspecified Subtype)

The "Angiotensin receptor (AT) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Angiotensin receptor (AT) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets